The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors

0544555 - ÚOCHB 2022 RIV US eng J - Článek v odborném periodiku
Otava, Tomáš - Šála, Michal - Li, F. - Fanfrlík, Jindřich - Devkota, K. - Perveen, S. - Chau, I. - Pakarian, P. - Hobza, Pavel - Vedadi, M. - Bouřa, Evžen - Nencka, Radim
The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors.
ACS Infectious Diseases. Roč. 7, č. 8 (2021), s. 2214-2220. ISSN 2373-8227
Grant CEP: GA MŠMT(CZ) EF16_019/0000729; GA MZd(CZ) NU20-05-00472
Institucionální podpora: RVO:61388963
Klíčová slova: COVID-19 * SARS-CoV-2 * methyltransferase * nsp14 nsp10 * structure-based design * inhibitors
Obor OECD: Microbiology
Impakt faktor: 5.578, rok: 2021
Způsob publikování: Omezený přístup
https://doi.org/10.1021/acsinfecdis.1c00131

In this study, we have focused on the structure-based design of the inhibitors of one of the two SARS-CoV-2 methyltransferases (MTases), nsp14. This MTase catalyzes the transfer of the methyl group from S-adenosyl-l-methionine (SAM) to cap the guanosine triphosphate moiety of the newly synthesized viral RNA, yielding the methylated capped RNA and S-adenosyl-l-homocysteine (SAH). As the crystal structure of SARS-CoV-2 nsp14 is unknown, we have taken advantage of its high homology to SARS-CoV nsp14 and prepared its homology model, which has allowed us to identify novel SAH derivatives modified at the adenine nucleobase as inhibitors of this important viral target. We have synthesized and tested the designed compounds in vitro and shown that these derivatives exert unprecedented inhibitory activity against this crucial enzyme. The docking studies nicely explain the contribution of an aromatic part attached by a linker to the position 7 of the 7-deaza analogues of SAH.
Trvalý link: http://hdl.handle.net/11104/0321402